Dr Cook grew up in Kenya, went to high school at St Edward’s, Oxford and studied medicine at St Bartholomew’s Medical School, London. He did a PhD at the National Heart and Lung Institute, UK and a Postdoctoral Fellowship at Harvard. He trained in cardiology and sub-specialized in cardiac MRI. He is Professor at Imperial College, London and Duke-National University of Singapore (Duke-NUS). He is a cardiologist at the National Heart Centre Singapore where he oversees the clinical MRI service. He is the former Director of the National Heart Research Institute Singapore and Program Director of the CVMD program at Duke-NUS. He is co-founder of Enleofen, a biotechnology company developing therapies for the treatment of fibrotic diseases.

His team discovered a critical role for the IL-11 cytokine in fibrosis and inflammation. He is co-founder of Enleofen, a Singaporean biotechnology company developing first-in-class antibody therapeutics for a range of fibro inflammatory diseases of the liver, kidney, heart, lung and bowel. The overarching goal of his research is to understand cardio metabolic disease mechanisms and to translate basic science discoveries to healthcare.